Phosphodiesterase 3A–Schlafen 12 complex (PDE3A–SLFN12 complex)

The Phosphodiesterase 3A–Schlafen 12 complex (PDE3A–SLFN12) is a protein–protein assembly that forms in cells upon binding of certain small molecules (termed “molecular glues”) such as DNMDP, anagrelide, nauclefine, or 17-β-estradiol to the catalytic site of PDE3A. This binding enables PDE3A to recruit and stabilize SLFN12, increasing SLFN12 RNase activity and resulting in strong inhibition of mRNA translation, which in turn leads to tumor cell apoptosis. The complex is a heterotetramer (dimer of PDE3A plus dimer of SLFN12) with a butterfly-like structure, whose formation can be promoted by several structurally distinct drugs. The therapeutic relevance is high, as the complex serves as a novel druggable target for cancer drug development, with the dual enzymatic and RNase activities offering multiple intervention points. PDE3A–SLFN12 is being explored as a predictive biomarker for drugs targeting this pathway, though further research is necessary to fully characterize its physiological and therapeutic roles and safety profile.

Other names

PDE3A-SLFN12PDE3A–Schlafen 12PDE3A–SLFN12 heterotetramer

“Molecular glue” mechanism: Small molecules bind to PDE3A’s catalytic pocket and stabilize the PDE3A–SLFN12 complex, triggering enhanced SLFN12 RNase and translational inhibition, which induces apoptosis in tumor cells, independent of PDE3A’s classical enzymatic activity. Some drugs (e.g., DNMDP, anagrelide) enhance complex formation and the pro-apoptotic activity. Enhanced interaction leads to protein translation blockade and apoptosis.